Cerebral hemorrhage
Drug research and approvals for cerebral hemorrhage: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 298 studies of cerebral hemorrhage are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 298
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Follow-up of Unruptured Intracranial Aneurysms With Ultra-High Field 7 Tesla MRINCT07949903 · Not applicable · Insel Gruppe AG, University Hospital Bern · starts Dec 18, 2024
- Chronic Subdural Hematoma RecurrenceNCT07937410 · Phase 1 / Phase 2 · Carilion Clinic · starts Jan 31, 2024
- Swiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in SmokersNCT07938775 · Not applicable · Insel Gruppe AG, University Hospital Bern · starts Jul 28, 2023
- AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational StudyNCT07924371 · Not reported · Hospital Universitari Vall d'Hebron Research Institute · starts Sep 28, 2026
- Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid HemorrhageNCT07923084 · Not reported · Insel Gruppe AG, University Hospital Bern · starts Jan 1, 2026
- Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICUNCT07917728 · Not reported · Columbia University · starts Oct 27, 2026
- PREcision MApping and NEuromodulation After Spontaneous Intracerebral Hemorrhage: The PREMANE TrialNCT07908264 · Not applicable · National University Hospital, Singapore · starts Aug 1, 2026
- French Validation of the SAHOT Outcome Scale After Subarachnoid HaemorrhageNCT07894666 · Not reported · Fondation Ophtalmologique Adolphe de Rothschild · starts Sep 28, 2026
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and…NCT07894107 · Not reported · Beijing Tiantan Hospital · starts Aug 3, 2026
Phase 3 4
- AlteplaseTissue-type plasminogen activator exogenous protein
- Eptacog alfa (activated)Coagulation factor VII exogenous protein
- FluoxetineSerotonin transporter inhibitor
- NicardipineVoltage-gated L-type calcium channel blocker
Phase 2 12 of 18
- CN-105
- EnalaprilAngiotensin-converting enzyme inhibitor
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- Tranexamic acidPlasminogen inhibitor
- DeferoxamineIron chelating agent
- LabetalolAdrenergic receptor antagonist
- Hydralazine
- CelecoxibCyclooxygenase-2 inhibitor
- DesmopressinVasopressin receptor agonist
- SpironolactoneMineralocorticoid receptor antagonist
- AnakinraInterleukin-1 receptor antagonist
- MirabegronBeta-3 adrenergic receptor agonist
Phase 1 or earlier 6
- MinocyclineBacterial 70S ribosome inhibitor
- FingolimodSphingosine 1-phosphate receptor agonist
- Starch
- GLP-1
- PF-05230907
- Phytonadione
How its trials ended
389 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 68 whose ending is known, 25% met their primary endpoint, 18% missed it and 57% stopped early.
- Ongoing13434%
- Completed, result not reported10126%
- Status unknown8622%
- Met its primary endpoint174%
- Stopped: other or unclear174%
- Missed its primary endpoint123%
- Stopped: enrollment or feasibility92%
- Stopped: sponsor or business decision51%
- Stopped: funding41%
- Stopped: lack of efficacy31%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA